Why Adenoviruses Are Commonly Chosen for Oncolytic Virotherapy
The correct answer is: Their broad receptor affinity and capacity for genetic modification.
Adenoviruses have become the predominant choice for oncolytic virotherapy, representing over 30% of cancer virotherapy clinical trials 1, primarily because they can infect a wide range of dividing and non-dividing cell types—sometimes achieving nearly 100% infection efficiency—and are readily amenable to genetic engineering 2.
Key Advantages of Adenoviruses for Oncolytic Applications
Broad Cellular Tropism and Infection Capability
Adenoviruses are double-stranded DNA viruses that are tropic for respiratory epithelium but can infect a broad spectrum of cell types 3. This versatility allows them to target diverse cancer types effectively. Unlike retroviruses, which require actively replicating cells for infection, adenoviruses do not necessitate host cell replication for gene transfer and expression 3, making them effective against both rapidly dividing and quiescent tumor cells.
Exceptional Genetic Modification Capacity
The primary reason adenoviruses dominate oncolytic virotherapy is their relative ease of genetic manipulation 4. Researchers can:
- Engineer tumor-selective replication by modifying viral genes to replicate preferentially in cancer cells 5
- Insert therapeutic transgenes to enhance anti-tumor immune responses 6
- Modify capsid proteins to alter receptor binding and improve tumor targeting 7
- Incorporate immune-modulating factors that reestablish or strengthen antitumor immunity 8
The adenoviral DNA functions in an extrachromosomal manner, which removes the theoretical possibility of mutagenesis occurring after insertion 3—a significant safety advantage over integrating viral vectors.
Why Other Answer Options Are Incorrect
Direct neutralization without immune involvement is incorrect because oncolytic adenoviruses work through both direct oncolysis AND immune activation 6, 8. A critical therapeutic mechanism is their ability to stimulate innate and adaptive immune responses against tumors.
High specificity for healthy cells is the opposite of reality—adenoviruses are engineered for tumor selectivity, not healthy cell targeting 5.
Natural immunity-enhancing properties without genetic alteration misses the point entirely. While adenoviruses are immunogenic, their therapeutic utility specifically depends on genetic modifications to enhance tumor selectivity and immunogenicity 7, 1.
Practical Manufacturing and Clinical Advantages
Beyond biological properties, adenoviruses offer practical benefits:
- Stability allowing purification to concentrations up to 10^13 particles/ml 2
- Self-assembly into particles of specific size (~100 nm) 2
- Well-understood replication machinery facilitating rational design 4
- Acceptable safety profile demonstrated across numerous clinical trials 7, 5
Important Caveat: Pre-existing Immunity
A significant limitation is that at least half of humans are already immune to Ad5 (the most commonly used serotype) 2. This has driven research into alternate adenovirus serotypes from the 54 different human serotypes available, allowing researchers to "mine" for viruses that can evade Ad5 immunity while maintaining oncolytic efficacy 2.